Empagliflozin Provides Kidney Protection and Heart Failure Risk Reduction in Acute Myocardial Infarction Patients
Empagliflozin shows promise in protecting kidney function and reducing heart failure risk in patients after acute myocardial infarction, according to recent research.
Recent research published in Nature Cardiovascular Research highlights the beneficial effects of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, in patients experiencing acute myocardial infarction (MI). The study analyzed data from a multicenter clinical trial involving 6,522 patients at risk for heart failure, assessing the drug's impact on kidney function and cardiovascular outcomes.
The findings reveal that empagliflozin helps preserve kidney function over a 24-month period, as indicated by stable estimated glomerular filtration rates (eGFR), contrasting with a decline observed in the placebo group. This kidney-protective effect was consistent regardless of baseline kidney health, demonstrating empagliflozin's broad applicability.
Moreover, patients treated with empagliflozin experienced a significant reduction in heart failure admissions and all-cause mortality, underscoring its cardiovascular benefits. Importantly, the study confirmed that initiating empagliflozin shortly after an acute MI was safe, with comparable short-term adverse event rates between treatment groups.
The study was led by Rahul Aggarwal, M.D., from Harvard Medical School, with safety and efficacy data supported by the pharmaceutical companies Boehringer Ingelheim and Eli Lilly. These results suggest that empagliflozin not only aids in managing blood sugar levels but also offers vital renal and cardiovascular protection during the critical recovery phase after a heart attack.
This evidence supports the integration of empagliflozin into treatment protocols for acute MI patients, highlighting its potential to improve long-term outcomes through kidney preservation and heart failure risk reduction.
For more details, see the original publication at: https://www.nature.com/articles/s44161-025-00657-7.
_source: https://medicalxpress.com/news/2025-06-empagliflozin-kidney-effects-acute-myocardial.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Improved Survival in Liver Cancer Patients Using Dual Immunotherapy
A novel dual immunotherapy approach combining nivolumab and ipilimumab has significantly improved survival rates and tumor control in patients with advanced liver cancer, offering new hope for treatment. The success of recent clinical trials has led to global approval, marking a major breakthrough in liver cancer management.
Advancements in Ultra-High Dose-Rate Radiation to Protect Normal Cells in Cancer Treatment
Innovative research from the University of Osaka reveals how ultra-high dose-rate carbon ion beams can protect normal cells during cancer therapy, potentially reducing side effects and improving treatment outcomes.
Artificial Intelligence Accelerates Infant Brain Development Assessment
A revolutionary AI-based method can assess infant brain maturity within minutes by analyzing EEG signals, enabling early detection of developmental delays and anomalies.
Breakthrough in Breast Cancer Research: New Tissue Biomarker Linked to Aggressiveness and Survival Outcomes
A new study from NIH identifies stromal tissue disruption as a key biomarker associated with aggressive breast cancer and poorer survival, offering promising avenues for early detection and intervention.